Richard Paulson - Apr 4, 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
President and CEO, Director
Signature
/s/Nancy Smith as Attorney-in-Fact for Richard Paulson
Stock symbol
KPTI
Transactions as of
Apr 4, 2025
Transactions value $
-$916
Form type
4
Date filed
4/7/2025, 04:59 PM
Previous filing
Mar 6, 2025
Next filing
May 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$916 -245 -0.3% $3.74 82.7K Apr 4, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.74 to $3.86, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.